Interestingly, in each case, the RET fusion remained suppressed on treatment raising the possibility multiple tumor clones with distinct drivers (either RET or KRAS) might co-exist at the baseline and behave differently under selective pressure of RET inhibition (Rosen et al. 2022). This evidence concerns the gene RET and neoplasm.